ライフサイエンスコーパス: sclerosing cholangitis

1 for potentially recurrent diseases (primary sclerosing cholangitis).

2 ous complications in patients with secondary sclerosing cholangitis.

3 ones, primary biliary cirrhosis, and primary sclerosing cholangitis.

4 Still rarer is its presentation as sclerosing cholangitis.

5 ngitis and the steroid-nonresponsive primary sclerosing cholangitis.

6 from UC that is not associated with primary sclerosing cholangitis.

7 f 38.5% observed among patients with primary sclerosing cholangitis.

8 n haplotypes are not associated with primary sclerosing cholangitis.

9 itis, primary biliary cirrhosis, and primary sclerosing cholangitis.

10 nancy, primary biliary cirrhosis and primary sclerosing cholangitis.

11 on does not appear to directly cause primary sclerosing cholangitis.

12 ve been detected in liver tissues in primary sclerosing cholangitis.

13 ancy, primary biliary cirrhosis, and primary sclerosing cholangitis.

14 established long-term treatment for primary sclerosing cholangitis.

15 ociation studies as risk factors for primary sclerosing cholangitis.

16 on in a patient with sickle cell disease and sclerosing cholangitis.

17 nset or immediately in patients with primary sclerosing cholangitis.

18 epresented 5.8% of patients (18 of 309) with sclerosing cholangitis.

19 patients with ulcerative colitis and primary sclerosing cholangitis.

20 with inflammatory bowel disease and primary sclerosing cholangitis.

21 nsplantation, and 3 had clinical evidence of sclerosing cholangitis.

22 amilial intrahepatic cholestasis and primary sclerosing cholangitis.

23 MC mediators may be therapeutic for primary sclerosing cholangitis.

24 f ERC, especially in patients with secondary sclerosing cholangitis.

25 response such as alcoholic liver disease or sclerosing cholangitis.

26 kocytes, and abrogates progression of murine sclerosing cholangitis.

27 iary tuberculosis with features of secondary sclerosing cholangitis.

28 t both primary biliary cirrhosis and primary sclerosing cholangitis.

29 ity of primary biliary cirrhosis and primary sclerosing cholangitis.

30 tal antimicrobials were those with secondary sclerosing cholangitis.

31 static entities, primary (PSC) and secondary sclerosing cholangitis.

32 primary biliary cirrhosis (16%), and primary sclerosing cholangitis (13%) with an odds ratio of 2.3,

33 ls with autoimmune diseases (18 with primary sclerosing cholangitis, 16 with autoimmune hepatitis, an

34 ry biliary cirrhosis (8.2%; P<0.05), primary sclerosing cholangitis (5.2%; P<0.05) or alcoholic cirrh

35 vs. 0.6%), hepatobiliary (including primary sclerosing cholangitis) (5.5% vs. 0.1%), pancreatic (1.7

36 nd primary biliary cirrhosis (7%) or primary sclerosing cholangitis (6%) and autoimmune cholangitis (

37 ancies (46.4%) and 114 patients with primary sclerosing cholangitis (62.3%).

38 tients with autoimmune hepatitis and primary sclerosing cholangitis (75% vs. 22%, P = .03) or autoimm

39 Primarily indications for ERC were sclerosing cholangitis (75%) and malignant stenosis (9.5

40 iliary epithelia of 30 patients with primary sclerosing cholangitis (a premalignant disease of the bi

41 itis, extensive colonic involvement, primary sclerosing cholangitis, a family history of colorectal c

42 une pancreatitis in association with primary sclerosing cholangitis, a syndrome with distinct clinico

43 primary biliary cirrhosis [PBC], and primary sclerosing cholangitis) account for approximately one th

44 in autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability o

45 in CLDs (primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, and chr

46 In patients with sclerosing cholangitis and acquired immunodeficiency syn

47 etween the autoimmune liver diseases primary sclerosing cholangitis and autoimmune hepatitis and infl

48 Primary biliary cirrhosis, primary sclerosing cholangitis and biliary atresia are thought t

49 nd pancreas is difficult to distinguish from sclerosing cholangitis and biliary/pancreatic malignanci

50 re up-regulated by cholangiocytes in primary sclerosing cholangitis and cholangiocarcinoma.

51 Primary sclerosing cholangitis and immunosuppressive use were no

52 astic bile duct inflammatory disease primary sclerosing cholangitis and in human cholangiocarcinoma s

53 1.9, P < .005) and in patients with primary sclerosing cholangitis and in severity were independentl

54 ular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is

55 as transplantation in a patient with primary sclerosing cholangitis and insulin-dependent diabetes me

56 apies for primary biliary cirrhosis, primary sclerosing cholangitis and intrahepatic cholestasis.

57 AP in the bile ductular reactions of primary sclerosing cholangitis and primary biliary cirrhosis pat

58 immune-mediated diseases, including primary sclerosing cholangitis and primary biliary cirrhosis, bu

59 dylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investi

60 lymphedema, protein loosing enteropathy, and sclerosing cholangitis and was diagnosed with lymphedema

61 en, with only 7 patients having a history of sclerosing cholangitis and/or inflammatory bowel disease

62 ic cholestasis, biliary atresia, and primary sclerosing cholangitis, and clinical trials of therapies

63 atitis C, primary biliary cirrhosis, primary sclerosing cholangitis, and cryptogenic cirrhosis.

64 Patients with autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis as

65 rent autoimmune hepatitis, recurrent primary sclerosing cholangitis, and recurrent primary biliary ci

66 Patients with ulcerative colitis and primary sclerosing cholangitis are at high risk for colonic dysp

67 ncluding autoimmune hepatitis and autoimmune sclerosing cholangitis ASC).

68 ary sclerosing cholangitis (PSC), autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (

69 chronic liver disease related to LCH-induced sclerosing cholangitis at 28 and 8 months, respectively.

70 gnoses of primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hepatitis

71 The most effective management of sclerosing cholangitis before the onset of cirrhosis rem

72 including primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, and progressive

73 CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithia

74 sitive biliary strictures resembling primary sclerosing cholangitis but with increased serum immunogl

75 rable with those in patients without primary sclerosing cholangitis, but there is a higher rate of re

76 s liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

77 es in a large group of patients with primary sclerosing cholangitis by using a recently developed pol

78 Differentiation of primary sclerosing cholangitis can be challenging because other

79 may play a role in biliary atresia, primary sclerosing cholangitis, cellular rejection, and primary

80 n of ulcerative colitis; duration of primary sclerosing cholangitis; Child-Pugh classification; and u

81 atment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, and dr

82 atment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, total

83 including primary biliary cirrhosis, primary sclerosing cholangitis, chronic hepatitis C, and postnec

84 samples (15 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), and the methylation st

85 arkers was validated (34 CCAs and 34 primary sclerosing cholangitis controls).

86 iliary atresia, congenital hepatic fibrosis, sclerosing cholangitis, cystic fibrosis, fulminant hepat

87 In a subgroup of patients, sclerosing cholangitis develops, which may lead to end-s

88 gram results, but the syndrome of autoimmune sclerosing cholangitis does not affect immediate prognos

89 arcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, ethanol, and cryptogenic.

90 r data collected included history of primary sclerosing cholangitis, family history of colorectal can

91 rbonyl-1,4-dihydrocollidine (DDC; a model of sclerosing cholangitis) for 4 weeks.

92 tients with autoimmune hepatitis and primary sclerosing cholangitis had a higher frequency of a poor

93 ural history of large and small duct primary sclerosing cholangitis has been reviewed.

94 Patients with primary sclerosing cholangitis have a poor prognosis; progressio

95 f patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreatitis in a

96 s associated with protection against primary sclerosing cholangitis have been elucidated.

97 antigen haplotype associations with primary sclerosing cholangitis have been investigated.

98 e gene polymorphisms associated with primary sclerosing cholangitis have been investigated.

99 Liver histology of sclerosing cholangitis improved, and extent of fibrosis

100 d primary biliary cirrhosis (PBC) or primary sclerosing cholangitis in 35.7%.

101 Primary sclerosing cholangitis in children can mimic autoimmune

102 ctive and accurate way of diagnosing primary sclerosing cholangitis in comparison with endoscopic ret

103 id transporter (ASBT), blocks progression of sclerosing cholangitis in mdr2(-/-) mice.

104 higher rate of retransplantation for primary sclerosing cholangitis in most centers.

105 hepatitis in children may be associated with sclerosing cholangitis in the absence of inflammatory bo

106 ure research efforts should focus on primary sclerosing cholangitis, in addition to primary biliary c

107 sights have arisen from studies of secondary sclerosing cholangitis, in which a similar clinical prof

108 Symptoms of primary sclerosing cholangitis include fatigue, jaundice, prurit

109 morphology observed in patients with primary sclerosing cholangitis-induced end-stage cirrhosis versu

110 Primary sclerosing cholangitis-inflammatory bowel disease probab

111 s such as primary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic cholestasis of preg

112 cholangitis (IAC), also called IgG4-related sclerosing cholangitis (IRSC), to the spectrum of chroni

113 Primary sclerosing cholangitis is a chronic cholestatic disease

114 Primary sclerosing cholangitis is a chronic cholestatic liver di

115 Primary sclerosing cholangitis is a chronic cholestatic liver di

116 Primary sclerosing cholangitis is a chronic cholestatic liver di

117 Primary sclerosing cholangitis is a chronic cholestatic liver di

118 Primary sclerosing cholangitis is a chronic cholestatic liver di

119 Primary sclerosing cholangitis is a chronic immune-mediated live

120 Primary sclerosing cholangitis is a chronic, progressive cholang

121 Primary sclerosing cholangitis is a progressive inflammatory dis

122 The genetic susceptibility to primary sclerosing cholangitis is associated, in part, with the

123 Liver histology in primary sclerosing cholangitis is characterized by a portal infl

124 Treatment of primary sclerosing cholangitis is confined to supportive measure

125 ate that the colitis associated with primary sclerosing cholangitis is pathophysiologically distinct

126 Primary sclerosing cholangitis is strongly linked to inflammator

127 ic heterogeneity among patients with primary sclerosing cholangitis is supported, and further gene po

128 Primary sclerosing cholangitis is the classic hepatobiliary mani

129 The etiopathogenesis of primary sclerosing cholangitis is unknown.

130 The best-studied drug in primary sclerosing cholangitis is ursodeoxycholic acid, which, d

131 vealed pancreatic duct strictures in two and sclerosing cholangitis-like appearance in one.

132 malignant PVT, after exclusion of those with sclerosing cholangitis, liver transplants, choledocholit

133 PBC livers, compared with normal and primary sclerosing cholangitis livers.

134 4 patients included autoimmune pancreatitis, sclerosing cholangitis, lymphoplasmacytic aortitis, sali

135 It is suggested that primary sclerosing cholangitis may have a bacterial cause.

136 Primary sclerosing cholangitis may overlap with autoimmune hepat

137 Sclerosing cholangitis may recur after transplantation,

138 Primary sclerosing cholangitis mice and patients have increased

139 model to explain the development of primary sclerosing cholangitis must take into account the fact t

140 era from patients with PBC (n = 47), primary sclerosing cholangitis (n = 15), and healthy volunteers

141 ancreatitis (n = 34) from those with primary sclerosing cholangitis (n = 17) and CA (n = 17).

142 ra from patients with PBC (n = 105), primary sclerosing cholangitis (n = 70), and rheumatoid arthriti

143 Strictures in patients with primary sclerosing cholangitis (n = 86) were analyzed separately

144 he causes of death were related to secondary sclerosing cholangitis (n=1), cardiac failure (n=1), and

145 disease: primary biliary cirrhosis (n= 19), sclerosing cholangitis (n=6), and autoimmune hepatitis (

146 imary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (

147 ing pancreatitis and cholangitis, n = 21; b) Sclerosing cholangitis, n = 9; c) Sclerosing pancreatiti

148 ectable or arising in the setting of primary sclerosing cholangitis, neoadjuvant chemoradiotherapy fo

149 in nonalcoholic fatty liver disease, primary sclerosing cholangitis, neonatal hemochromatosis, acute

150 Neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome is a liver disea

151 vancements in the areas of childhood primary sclerosing cholangitis, nonalcoholic fatty liver disease

152 ease other than primary biliary cirrhosis or sclerosing cholangitis, number of units of red blood cel

153 the initial steps toward the development of sclerosing cholangitis or bile duct cancers in XHIM pati

154 ine (39%) of 23 patients with either primary sclerosing cholangitis or biliary atresia, compared with

155 4-dihydrocollidine (DDC) feeding (a model of sclerosing cholangitis) or bile duct ligation (BDL).

156 st LT for primary biliary cirrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (group I)

157 all P = .003), as well as absence of primary sclerosing cholangitis (P = .011).

158 tis C virus (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9).

159 human liver samples from control or primary sclerosing cholangitis patients were evaluated for MC ma

160 s been demonstrated in a subgroup of primary sclerosing cholangitis patients, which may indicate an o

161 bile ducts from the hilar region of primary sclerosing cholangitis patients.

162 ve CCA detection, particularly among primary sclerosing cholangitis patients.

163 Underlying primary sclerosing cholangitis, percutaneous biliary intubation,

164 e most studied medical treatment for primary sclerosing cholangitis; pilot studies suggest a possible

165 NA (mRNA) in PBC liver compared with primary sclerosing cholangitis (PSC) (P <.05) or normal controls

166 The prevalence of primary sclerosing cholangitis (PSC) among patients with inflamm

167 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and assessed both vertebral

168 sis occurs during the progression of primary sclerosing cholangitis (PSC) and is characterized by acc

169 Primary sclerosing cholangitis (PSC) and primary biliary cholang

170 ding bile duct epithelium) varies in primary sclerosing cholangitis (PSC) and primary biliary cirrhos

171 Patients with primary sclerosing cholangitis (PSC) are at an increased risk fo

172 Patients with primary sclerosing cholangitis (PSC) are at increased risk for d

173 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune c

174 tologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated.

175 primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) are scarce.

176 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are uncommon liver diseases

177 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) at 3 transplantation center

178 s serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve surviv

179 nd hepatic histology compatible with primary sclerosing cholangitis (PSC) but normal findings on chol

180 eased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the

181 Recurrence of primary sclerosing cholangitis (PSC) following liver transplanta

182 Patients with primary sclerosing cholangitis (PSC) have a significantly increa

183 proximately 60%-80% of patients with primary sclerosing cholangitis (PSC) have concurrent ulcerative

184 giography (MRC) for the diagnosis of primary sclerosing cholangitis (PSC) have described comparable a

185 developing varices in patients with primary sclerosing cholangitis (PSC) have not been well studied

186 The epidemiology of primary sclerosing cholangitis (PSC) in the United States is unk

187 Primary sclerosing cholangitis (PSC) is a chronic bile duct dise

188 Primary sclerosing cholangitis (PSC) is a chronic cholestatic di

189 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

190 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

191 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

192 Primary sclerosing cholangitis (PSC) is a chronic fibroinflammat

193 Primary sclerosing cholangitis (PSC) is a chronic, fibroinflamma

194 Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, f

195 Primary sclerosing cholangitis (PSC) is a disease of unknown cau

196 Primary sclerosing cholangitis (PSC) is a rare but important liv

197 Primary sclerosing cholangitis (PSC) is a rare progressive disor

198 Primary sclerosing cholangitis (PSC) is a rare, but serious, cho

199 Primary sclerosing cholangitis (PSC) is a severe liver disease o

200 Primary sclerosing cholangitis (PSC) is an incurable cholangiopa

201 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary

202 Genetic susceptibility to primary sclerosing cholangitis (PSC) is associated with the exte

203 Primary sclerosing cholangitis (PSC) is increasingly diagnosed i

204 er, with the exception of Notch-3 in primary sclerosing cholangitis (PSC) livers, expression was abse

205 Patients with primary sclerosing cholangitis (PSC) may be at higher risk of ma

206 Patients with primary sclerosing cholangitis (PSC) may develop and bleed from

207 Pathogenesis of primary sclerosing cholangitis (PSC) may involve impaired bile a

208 features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and without

209 stricture formation in patients with primary sclerosing cholangitis (PSC) or after liver transplantat

210 ed specifically in cholangiocytes of primary sclerosing cholangitis (PSC) patients and in mice subjec

211 Primary sclerosing cholangitis (PSC) patients pose a particularl

212 Primary sclerosing cholangitis (PSC) patients suffer from comorb

213 Primary sclerosing cholangitis (PSC) predisposes individuals to

214 o summarize publications on juvenile primary sclerosing cholangitis (PSC) published over the past 5 y

215 The possibility of primary sclerosing cholangitis (PSC) recurrence after liver tran

216 The pathogenesis of primary sclerosing cholangitis (PSC) remains poorly understood.

217 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) seen at the Mayo Clinic.

218 For patients with primary sclerosing cholangitis (PSC) suffering from bacterial ch

219 Primary sclerosing cholangitis (PSC) was present in 31/126 CCA p

220 underwent liver transplantation for primary sclerosing cholangitis (PSC) were analyzed using person-

221 story of either IBD (29 patients) or primary sclerosing cholangitis (PSC) without evidence of IBD bef

222 mens, including 64 with PBC, 19 with primary sclerosing cholangitis (PSC), 6 with non-A, non-B hepati

223 Primary sclerosing cholangitis (PSC), a chronic inflammatory liv

224 Primary sclerosing cholangitis (PSC), age, history of cholecyste

225 ects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy controls.

226 ses primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic liver diseas

227 tients with ulcerative colitis (UC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (

228 Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors.

229 atic tissue from patients with AP or primary sclerosing cholangitis (PSC), as well as from mice.

230 ogy and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune sclerosing chol

231 In primary sclerosing cholangitis (PSC), bile fluid is frequently c

232 tolithiasis and 20 archival cases of primary sclerosing cholangitis (PSC), both of which are risk con

233 bowel disease may be accompanied by primary sclerosing cholangitis (PSC), but seldom primary biliary

234 arly primary biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time with anat

235 Primary sclerosing cholangitis (PSC), first described in the mid

236 for detecting cholangiocarcinoma in primary sclerosing cholangitis (PSC), particularly when used seq

237 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment

238 and disease course in patients with primary sclerosing cholangitis (PSC).

239 n of cholangiopathies, in particular primary sclerosing cholangitis (PSC).

240 not been well studied in those with primary sclerosing cholangitis (PSC).

241 deoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC).

242 s; however, no information exists in primary sclerosing cholangitis (PSC).

243 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

244 ated inflammatory diseases including primary sclerosing cholangitis (PSC).

245 primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).

246 iocyte senescence has been linked to primary sclerosing cholangitis (PSC).

247 nts with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC).

248 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

249 o be ineffective in the treatment of primary sclerosing cholangitis (PSC).

250 loproteinase 3) on susceptibility to primary sclerosing cholangitis (PSC).

251 wel disease differentiated them from primary sclerosing cholangitis (PSC).

252 e primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC).

253 essment of survival in patients with primary sclerosing cholangitis (PSC).

254 with end-stage liver disease due to primary sclerosing cholangitis (PSC).

255 fibrosis in animal models and human primary sclerosing cholangitis (PSC).

256 ng disease activity and prognosis in primary sclerosing cholangitis (PSC).

257 iated biliary injury is a feature of primary sclerosing cholangitis (PSC).

258 e, other benign disease, tumour, and primary sclerosing cholangitis (PSC).

259 or management of adult patients with primary sclerosing cholangitis (PSC).

260 andard of reference for diagnosis of primary sclerosing cholangitis (PSC).

261 reatment for patients with end-stage primary sclerosing cholangitis (PSC); however, selection criteri

262 reported in 9%-15% of patients with primary sclerosing cholangitis (PSC); it is not clear whether th

263 ignancy was highest in patients with primary sclerosing cholangitis (PSC; 22% at 10 years) or alcohol

264 ary biliary cirrhosis (PBC; n=3052), primary sclerosing cholangitis (PSC; n=3854), hepatitis C virus

265 reater primary dysfunction GF, while primary sclerosing cholangitis (PSC; P=0.0002) implied greater v

266 imary biliary cholangitis [PBC], and primary sclerosing cholangitis [PSC]), we built a comprehensive

267 bacteria in the etiopathogenesis of primary sclerosing cholangitis remains to be determined.

268 While the clinical features of sclerosing cholangitis secondary to opportunistic infect

269 enesis and possible therapy of the secondary sclerosing cholangitis seen in AIDS patients with biliar

270 of colitis, duration of colitis, duration of sclerosing cholangitis, severity of liver disease, and s

271 ating lymphocytes from patients with primary sclerosing cholangitis showed rolling adhesion on MAdCAM

272 carcinoma (HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deterioration

273 le modeling using RC, FISH, age, and primary sclerosing cholangitis status can be used to estimate th

274 , trisomy FISH, suspicious cytology, primary sclerosing cholangitis status, and age were associated w

275 requently (P < .05) in patients with primary sclerosing cholangitis than in patients with cirrhosis c

276 requently (P < .05) in patients with primary sclerosing cholangitis than in the other 472 patients.

277 Yet different from patients with primary sclerosing cholangitis, the expression of CCL25 remained

278 do not confer any susceptibility to primary sclerosing cholangitis; the role of intercellular adhesi

279 ease, non-alcoholic steatohepatitis, primary sclerosing cholangitis, total parenteral nutrition-assoc

280 emonstrated in biliary lithiasis and primary sclerosing cholangitis, two cholangiopathies regarded as

281 tween inflammatory bowel disease and primary sclerosing cholangitis underscores the need to further u

282 Cirrhosis not related to primary sclerosing cholangitis was associated with both intrahep

283 Primary sclerosing cholangitis was associated with intrahepatic

284 Primary sclerosing cholangitis was more strongly associated with

285 d inflammatory bowel disease without primary sclerosing cholangitis was not associated with any CCA s

286 A paucity of research studies on primary sclerosing cholangitis was noted in this review and futu

287 with inflammatory bowel disease and primary sclerosing cholangitis was the identification of an incr

288 For all recipients, female sex and primary sclerosing cholangitis were associated with improved sur

289 disease, and those with concomitant primary sclerosing cholangitis were at increased risk.

290 s with end-stage cirrhosis caused by primary sclerosing cholangitis were compared with the frequency

291 Patients suspected to have secondary sclerosing cholangitis were excluded.

292 ease other than primary biliary cirrhosis or sclerosing cholangitis were independently associated (P<

293 ther inflammatory disorders (such as primary sclerosing cholangitis), whereas it decreases when patie

294 second patient was a 26-year-old female with sclerosing cholangitis who presented with encephalopathy

295 patients with ulcerative colitis and primary sclerosing cholangitis who were undergoing colonoscopic

296 icult, particularly in patients with primary sclerosing cholangitis, who are at risk of developing th

297 ciated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histoco

298 itis with pancreatic pseudotumour, n = 7; e) Sclerosing cholangitis with hepatic pseudotumour, n = 3;

299 mples from patients with and without primary sclerosing cholangitis with higher levels of sensitivity

300 Sclerosing cholangitis with strong autoimmune features i